Investors Press Releases Cardiol Therapeutics Announces Filing of 2019 Year-end Financial Statements and MD&A March 26, 2020 Cardiol Therapeutics Signs Supplier Agreement with Medical Cannabis by Shoppers, a Subsidiary of Shoppers Drug Mart Inc. March 18, 2020 Cardiol Therapeutics Receives Health Canada Approval for Phase 1 Study of its Pharmaceutically Produced Cannabidiol (CBD) Formulation March 05, 2020 Cardiol Therapeutics’ Exclusive Manufacturing Partner Receives Three-Year Renewal and Amendment of its Cannabis Act License from Health Canada January 15, 2020 Cardiol Therapeutics Appoints Michael J. Willner, Esq. as Business Advisor December 18, 2019 Cardiol Therapeutics Appoints Former GW Pharmaceuticals Executive Colin Stott to its Board of Directors December 03, 2019 Cardiol Therapeutics comments on the Descheduling of Purisys Cannabinoid Ingredients by U.S. Drug Enforcement Agency November 25, 2019 Cardiol Therapeutics Announces Clinical Steering Committee for Phase 2 International Trial in Acute Myocarditis Using CardiolRx™100 November 19, 2019 Cardiol Therapeutics Announces Completion of Manufacturing Scale-up for Commercialization of CardiolRx™100 October 01, 2019 Cardiol Therapeutics to Webcast Live at VirtualInvestorConferences.com on September 12th September 05, 2019 Page 2 of 5«12345»
